Related Experiment Video
Updated: Aug 11, 2026
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy
Alan Nichol1, Peter Chung, Gina Lockwood
1Radiation Medicine Program, Princess Margaret Hospital and University of Toronto, Toronto, Canada.
Background And Purpose:
To prospectively evaluate toxicity, biochemical failure-free survival (bFFS) and biopsy-proven local control for prostate cancer patients treated with 75.6 Gy in 42 fractions using 6-field conformal radiotherapy to prostate alone.
Patients And Methods:
From 1997 to 1999, 140 patients with T1-2NxM0, Gleason score
Results:
Clinically important acute toxicities were gastrointestinal (GI) grade 2: 22% and 3: 0%, and genitourinary (GU) grade 2: 24% and 3: 2%. Late physician-assessed toxicities were GI>or=grade 2: 2%, and GU>or=grade 2: 1%. The 3-year bFFS of patients failure-free before biopsy was 93% (95% CI: 83-100) from a negative biopsy and 22% (95% CI: 0-56) from a positive biopsy (P=0.001). Patients reported significantly more late toxicity than physicians (GI: P=0.003, GU: P<0.001). At 5.0 years median follow-up, cause-specific survival was 98% (95% CI: 96-100), overall survival was 91% (95% CI: 86-97), and bFFS was 55% (95% CI: 45-64).
Conclusions:
75.6 Gy caused modest levels of acute and late toxicity. Three-year biopsies predicted subsequent biochemical outcome.
